OpenOnco
UA EN
Plan Builder Onco Wiki Tumor Board

Onco Wiki / Biomarker

HCV status (anti-HCV antibody screening)

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

IDBIO-HCV-STATUS
TypeBiomarker
Aliases
HCV serologyHepatitis C screeningHepatitis C virus statusanti-HCVСтатус HCV (антитіла анти-HCV)
Statusreviewed 2026-04-26 | pending_clinical_signoff
DiseasesNone declared
SourcesSRC-EASL-HCV-2023 SRC-NCCN-BCELL-2025

Biomarker Facts

Biomarker typeviral_serology
Measurement
MethodAnti-HCV antibody (third-generation EIA). Reflex to BIO-HCV-RNA (quantitative PCR) when anti-HCV+ to distinguish active infection (RNA detectable) from resolved / cleared (RNA undetectable, antibody persists for life).
Unitscategorical: anti-HCV+ | anti-HCV-
Related biomarkersBIO-HCV-RNA BIO-HBV-STATUS BIO-HIV-STATUS

Notes

Screening test; positive result is necessary but not sufficient evidence of active HCV (false positives in autoimmune disease, cleared infections retain antibodies indefinitely). Active infection requires BIO-HCV-RNA detectable; rules engine should branch on HCV-RNA positivity, not antibody alone, for any DAA / treatment decision. Currently consumed by: ALGO-MM-1L (etiology rail — coordinate DAA with hepatologist if HCV+). Companion biomarker BIO-HCV-RNA carries the quantitative load and drives the HCV-MZL etiologically-driven algorithm. STATUS is the cheap screening; RNA is the actionable confirmation. reviewer_signoffs: 0 # STUB — pending two Clinical Co-Lead approvals

Used By

Algorithms

Biomarker

Indications

Questionnaires